FULC · Company research
Fulcrum Therapeutics, Inc. (FULC): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
17records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? - Yahoo Finance | Fulcrum (FULC) is Allocating 95% of the Combined Company to Slate and PIPE Investors. Is the $270M Dividend Enough? Yahoo Finance | View source ↗ | Yahoo Finance | Aug 25, 2026 | neutral | 0 | 0.6 |
| Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate - Stock Titan | Fulcrum Therapeutics (NASDAQ: FULC) backs $245M migraine venture with Slate Stock Titan | View source ↗ | Stock Titan | Aug 17, 2026 | neutral | 0 | 0.6 |
| What's Going On With Fulcrum Therapeutics Stock Monday? - Fulcrum Therapeutics (NASDAQ:FULC) - Benzinga | What's Going On With Fulcrum Therapeutics Stock Monday? - Fulcrum Therapeutics (NASDAQ:FULC) Benzinga | View source ↗ | Benzinga | Aug 17, 2026 | neutral | 0 | 0.6 |
| FULC: Merger forms a migraine-focused biotech with $245M financing and clinical milestones ahead - TradingView | FULC: Merger forms a migraine-focused biotech with $245M financing and clinical milestones ahead TradingView | View source ↗ | TradingView | Aug 17, 2026 | neutral | 0 | 0.6 |
| Fulcrum Therapeutics: Buy It For The Strategic Reset (NASDAQ:FULC) - Seeking Alpha | Fulcrum Therapeutics: Buy It For The Strategic Reset (NASDAQ:FULC) Seeking Alpha | View source ↗ | Seeking Alpha | Jul 31, 2026 | neutral | 0 | 0.6 |
| FULC Forecast — Price Target — Prediction for 2027 - TradingView | FULC Forecast — Price Target — Prediction for 2027 TradingView | View source ↗ | TradingView | Jun 25, 2026 | neutral | 0 | 0.6 |
| Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky - PR Newswire | Fulcrum Therapeutics, Inc. (FULC) Securities Fraud Investigation - Levi & Korsinsky PR Newswire | View source ↗ | PR Newswire | Jun 9, 2026 | neutral | 0 | 0.6 |
| A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring - Yahoo Finance | A Look At Fulcrum Therapeutics (FULC) Valuation After Scrapping Lead Sickle Cell Drug And Restructuring Yahoo Finance | View source ↗ | Yahoo Finance | Jun 5, 2026 | neutral | 0 | 0.6 |
| FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud - Business Wire | FULC Investor Alert: Levi & Korsinsky Investigates Fulcrum Therapeutics, Inc. (FULC) for Potential Securities Fraud Business Wire | View source ↗ | Business Wire | Jun 4, 2026 | neutral | 0 | 0.6 |
| FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End - Yahoo Finance | FULC Stock Crashes as Cancer Risk Forces Its Only Drug Program's End Yahoo Finance | View source ↗ | Yahoo Finance | Jun 3, 2026 | neutral | 0 | 0.6 |
| Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options - Simply Wall Street | Why Fulcrum Therapeutics (FULC) Is Down 53.6% After Ending Pociredir And Exploring Strategic Options Simply Wall Street | View source ↗ | Simply Wall Street | Jun 3, 2026 | neutral | 0 | 0.6 |
| Fulcrum Therapeutics (FULC) Halts Sickle Cell Drug Development, Stock Plummets - GuruFocus | Fulcrum Therapeutics (FULC) Halts Sickle Cell Drug Development, Stock Plummets GuruFocus | View source ↗ | GuruFocus | Jun 2, 2026 | neutral | 0 | 0.6 |
| FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk - Stocktwits | FULC Stock Slumps Nearly 50% After Hours As FDA Kills Only Clinical Program Over Cancer Risk Stocktwits | View source ↗ | Stocktwits | Jun 1, 2026 | neutral | 0 | 0.6 |
| After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP - Investing.com | After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP Investing.com | View source ↗ | Investing.com | Jun 1, 2026 | neutral | 0 | 0.6 |
| FDA cancer-risk stance ends sickle cell drug; Fulcrum weighs options - Stock Titan | FDA cancer-risk stance ends sickle cell drug; Fulcrum weighs options Stock Titan | View source ↗ | Stock Titan | Jun 1, 2026 | neutral | 0 | 0.6 |
| After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP By Investing.com - Investing.com Nigeria | After-Hours Stock Movers: HPE, CRDO, FULC, ABVX, MCHP By Investing.com Investing.com Nigeria | View source ↗ | Investing.com Nigeria | Jun 1, 2026 | neutral | 0 | 0.6 |
| FULCRUM THERAPEUTICS ($FULC) Releases Q4 2025 Earnings - Quiver Quantitative | FULCRUM THERAPEUTICS ($FULC) Releases Q4 2025 Earnings Quiver Quantitative | View source ↗ | Quiver Quantitative | Feb 24, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.